case_images: PMC7417602_01
case_images: Planned treatment schedule.
case_images: fonc-10-01155-g0001.jpg
case_images: PMC7417602_01_fonc-10-01155-g0001.jpg
case_images: F1
case_images: The yE patient with secondary CIRS stage, KRAS mutant c.35 G>T MCRC rapidly relapsing after adjuvant XelOx chemotherapy, previously experiencing LTS-ms, underwent first-line modulated treatment according to the following schedule: aflibercept (4 mg/kg) d1,15-irinotecan (120 mg/m2) d1,15-5-fluorouracil (750 mg/m2/day) dd1-4, 15-18, cycles repeated every 28 days (Figure 1), based on previously reported doublet fluorouracil/irinotecan schedule.
case_images: CT scan images showing bilateral lung metastases early relapsed after adjuvant chemotherapy (A) and re-evaluated after first-line aflibercept/chemotherapy (B).
case_images: fonc-10-01155-g0002.jpg
case_images: PMC7417602_01_fonc-10-01155-g0002.jpg
case_images: F2
case_images: First evaluation of response by CT scan showed partial response (PR) of secondary lung metastases with intra-lesion necrosis (Figure 2).
case_images: CT scan images showing bilateral lung metastases relapsed after first-line chemotherapy (A) and re-evaluated after aflibercept/chemotherapy re-introduction (B).
case_images: fonc-10-01155-g0003.jpg
case_images: PMC7417602_01_fonc-10-01155-g0003.jpg
case_images: F3
case_images: First evaluation of response by CT scan showed 50% PR of secondary lung nodules (Figure 3).
case_images: Timeline.
case_images: fonc-10-01155-g0004.jpg
case_images: PMC7417602_01_fonc-10-01155-g0004.jpg
case_images: F4